FDA D.I.S.C.O. Burst Edition: FDA approval of Scemblix (asciminib) for patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, previously treated with tyrosine kinase inhibitors, and for adult patients in chronic phase with the T315I mutation
0:00
4:00
Listen to a soundcast of the October 29, 2021, FDA approval of Scemblix (asciminib) for patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, previously treated with tyrosine kinase inhibitors, and for adult patients in chronic phase with the T315I mutation
Otros episodios de "FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)"
No te pierdas ningún episodio de “FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)”. Síguelo en la aplicación gratuita de GetPodcast.